Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf158 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Svea Cheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh School of Medicine, Division of Hematology/Oncology, Pittsburgh, PA 15213, United States. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Colorectal Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, University of Pittsburgh, National Cancer Institute.
Abstract (Originalsprache)
Background
Amplification of human epidermal growth factor receptor-2 (HER2) can be targeted with HER2-directed combination therapies for patients with colorectal cancer (CRC). Evolving data from clinical trials suggest mutations in KRAS and PIK3CA, downstream effectors of HER2, may confer resistance to HER2 blockade. However, the true incidence of these alterations in HER2-amplified CRC is largely unknown. In this large cohort study, we investigated the incidence of RAS/RAF and PIK3CA alterations among patients with HER2-amplified CRC.
Methods
Twenty-one studies containing CRC specimens as of April 2023 were sampled using cBioPortal for Cancer Genomics. Clinical, specimen, copy number alteration, and somatic mutation data were aggregated and processed to generate ~30 analysis-ready fields encompassing demographic variables, HER2 amplification, and KRAS/NRAS/PIK3CA/BRAF/MAPK1/MAPK3/HER2 mutations.
Results
Among 4823 patients with CRC, the incidence of HER2 amplification was 2.6% (87/4823), with a higher incidence in male, Asian, and Black patients. Among patients with HER2-amplified CRC, the incidence of KRAS, NRAS, and PIK3CA mutations was 21.8% (19/87) (27.9% [17/61] in colon cancer, 7.7% [2/26] in rectal cancer), 3.4% (3/87)(3.3% [2/61] in colon cancer, 3.8% [1/26] in rectal cancer), and 11.5% (10/87) (13.1% [8/61] in colon cancer, 7.7% [2/26] in rectal cancer), respectively. No BRAF, MAPK1, or MAPK3 mutations were identified. Notably, concurrent HER2 mutation and amplification occurred at an incidence of 16.1% (14/87) (16.4% [10/61] in colon cancer, 15.4% [4/26] in rectal cancer). Median overall survival for all stage patients was significantly lower in patients with HER2-amplified CRC (37.2 months) than in patients with CRC without HER2 amplification (74.9 months) (P = .038).
Conclusions
RAS, PIK3CA, and HER2 mutations can commonly co-occur with HER2 amplification, with higher rates in colon cancer than rectal cancer. These findings underscore biological heterogeneity and the importance of molecular profiling in identifying potential resistance before initiation of HER2-directed therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Pittsburgh School of Medicine, Division of Hematology/Oncology, Pittsburgh, PA 15213, United States.
- Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States.
- UPMC Hillman Cancer Center, Division of Hematology/Oncology at UPMC Shadyside, Pittsburgh, PA 15232, United States.
- Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA 98109, United States.
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.
- Division of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States.
ORCID-Profile: Ibrahim Halil Sahin
Förderung
- NCI NIH HHS
- University of Pittsburgh
- National Cancer Institute
Zitieren
APA
Cheng, S., Gomez, C. G., Ferrell, M., Giza, R., Syed, M. P., Magge, T., Gorantla, V., Hsieh, R. W., Bao, R., Singhi, A., Saeed, A., & Sahin, I. H. (2025). Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis. The Oncologist. https://doi.org/10.1093/oncolo/oyaf158
Vancouver
Cheng S, Gomez CG, Ferrell M, Giza R, Syed MP, Magge T, et al. Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis. The Oncologist. 2025. doi:10.1093/oncolo/oyaf158
BibTeX
@article{Cheng2025,
author = {Cheng, Svea and Gomez, Cyndi Gonzales and Ferrell, Morgan and Giza, Richard and Syed, Masood Pasha and Magge, Tara and Gorantla, Vikram and Hsieh, Ronan W and Bao, Riyue and Singhi, Aatur and Saeed, Anwaar and Sahin, Ibrahim Halil},
title = {Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf158}
}
EUVIMED